# Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

> **NCT05952934** · PHASE2 · RECRUITING · sponsor: **University of Arkansas** · enrollment: 100 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** 0.5 mL Candin®/injection
- **OTHER:** Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)

## Key facts

- **NCT ID:** NCT05952934
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-12
- **Primary completion:** 2031-07-31
- **Final completion:** 2031-07-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952934, "Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05952934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*